Skip to main content
Print Save

Generic Rayos Availability

Last updated on Mar 9, 2023.

Rayos is a brand name of prednisone, approved by the FDA in the following formulation(s):

RAYOS (prednisone - tablet, delayed release;oral)

  • Manufacturer: HORIZON
    Approval date: July 26, 2012
    Strength(s): 1MG [RLD] [AB], 2MG [RLD] [AB], 5MG [RLD] [AB]

Has a generic version of Rayos been approved?

A generic version of Rayos has been approved by the FDA. However, this does not mean that the product will necessarily be commercially available - possibly because of drug patents and/or drug exclusivity. The following products are equivalent to Rayos and have been approved by the FDA:

prednisone tablet, delayed release;oral

  • Manufacturer: ACTAVIS LABS FL INC
    Approval date: April 25, 2017
    Strength(s): 1MG [AB], 2MG [AB], 5MG [AB]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Rayos. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: Generic Drug FAQ.

Related patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • Delayed release tablet with defined core geometry
    Patent 8,168,218
    Issued: May 1, 2012
    Inventor(s): Vergnault; Guy & Grenier; Pascal & Dragan; Christophe
    Assignee(s): Jagotec AG

    A press-coated tablet comprising a core containing an drug substance, and a coating, the core being disposed within the coating such that the coating has a first thickness about an axis A-B and a thickness about an orthogonal axis X-Y, such that the coating about the axis X-Y is thicker than the coating about the axis A-B, and is adapted to provide a lag time of between about 2 to 6 hours during which substantially no drug substance is released.

    Patent expiration dates:

    • January 7, 2028
      ✓ 
      Patent use: TREATMENT OF RHEUMATOLOGIC, ALLERGIC, PULMONARY, GASTROINTESTINAL, DERMATOLOGIC DISEASES OR CONDITIONS BY THE USE OF A DELAYED RELEASE 5MG PREDNISONE TABLET
      ✓ 
      Drug product
  • Delayed release tablet with defined core geometry
    Patent 8,309,124
    Issued: November 13, 2012
    Inventor(s): Vergnault; Guy & Grenier; Pascal & Dragan; Christophe
    Assignee(s): Jagotec AG

    A tablet comprising a core containing an active agent, and a coating, the core being disposed within the coating such that the coating has a thickness about a longitudinal axis (X-Y) of about 4.85 to 4.95 mm. The position of the core within the coating dictating that the active agent is released rapidly after a lag time during which time no active agent is released.

    Patent expiration dates:

    • April 23, 2024
      ✓ 
      Patent use: TREATMENT OF DISEASES OR CONDITIONS BY THE USE OF A DELAYED RELEASE 1, 2, OR 5 MG PREDNISONE TABLET
    • April 23, 2024
  • Delayed release tablet with defined core geometry
    Patent 8,394,407
    Issued: March 12, 2013
    Assignee(s): Jagotec AG

    A tablet comprising a core containing an active agent, and a coating, the core being disposed within the coating such that the coating has a thickness about a longitudinal axis (X-Y) of about 4.85 to 4.95 mm. The position of the core within the coating dictating that the active agent is released rapidly after a lag time during which time no active agent is released.

    Patent expiration dates:

    • April 23, 2024
      ✓ 
      Patent use: TREATMENT OF DISEASES OR CONDITIONS BY THE USE OF A DELAYED-RELEASE 1,2, OR 5MG PREDNISONE TABLET
      ✓ 
      Drug product
  • Delayed release tablet with defined core geometry
    Patent 9,040,085
    Issued: May 26, 2015
    Assignee(s): Jagotec AG

    A tablet comprising a core containing an active agent, and a coating, the core being disposed within the coating such that the coating has a thickness about a longitudinal axis (X-Y) of about 4.85 to 4.95 mm. The position of the core within the coating dictating that the active agent is released rapidly after a lag time during which time no active agent is released.

    Patent expiration dates:

    • April 23, 2024
      ✓ 
      Patent use: TREATMENT OF DISEASES OR CONDITIONS BY THE USE OF A DELAYED-RELEASE 1,2, OR 5MG PREDNISONE TABLET
  • Delayed release tablet with defined core geometry
    Patent 9,186,332
    Issued: November 17, 2015
    Assignee(s): Jagotec AG

    A tablet comprising a core containing an active agent, and a coating, the core being disposed within the coating such that the coating has a thickness about a longitudinal axis (X-Y) of about 4.85 to 4.95 mm. The position of the core within the coating dictating that the active agent is released rapidly after a lag time during which time no active agent is released.

    Patent expiration dates:

    • April 23, 2024
      ✓ 
      Patent use: TREATMENT OF DISEASES OR CONDITIONS BY THE USE OF A DELAYED-RELEASE 1,2, OR 5MG PREDNISONE TABLET
  • Delayed-release glucocorticoid treatment of rheumatoid disease
    Patent 9,504,699
    Issued: November 29, 2016
    Assignee(s): HZNP Limited

    The present invention refers to the treatment of a rheumatic disease and/or osteoarthritis by administering a delayed-release dosage form of a glucocorticoid to a subject in need thereof.

    Patent expiration dates:

    • August 3, 2027
      ✓ 
      Patent use: TREATMENT OF DISEASES OR CONDITIONS BY THE USE OF A DELAYED-RELEASE 1,2, OR 5MG PREDNISONE TABLET

Glossary

Term Definition
Drug Patent A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug Exclusivity Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLD A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.
AB Products meeting necessary bioequivalence requirements. Multisource drug products listed under the same heading (e.g. identical active ingredients, dosage form, and routes of administration) and having the same strength (see Therapeutic Equivalence-Related Terms, Pharmaceutical Equivalents) generally will be coded AB if a study is submitted demonstrating bioequivalence. In certain instances, a number is added to the end of the AB code to make a three character code (e.g. AB1, AB2, AB7). Three-character codes are assigned only in situations when more than one reference listed drug of the same strength has been designated under the same heading. Two or more reference listed drugs are generally selected only when there are at least two potential reference drug products which are not bioequivalent to each other. If a study is submitted that demonstrates bioequivalence to a specific listed drug product, the generic product will be given the same three-character code as the reference listed drug it was compared against.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer